Literature DB >> 32484306

Clinical characteristics and quality of life, depression, and anxiety in adults with neurofibromatosis type 1: A nationwide study.

Karoline Doser1,2, Elisabeth Wreford Andersen3, Line Kenborg1, Susanne Oksbjerg Dalton4,5, Jens Richardt Møllegaard Jepsen6,7, Anja Krøyer1, John Østergaard8, Hanne Hove9, Sven Asger Sørensen10, Christoffer Johansen2,11, John Mulvihill12, Jeanette Falck Winther1,13, Pernille Envold Bidstrup2,14.   

Abstract

Neurofibromatosis type 1 (NF1) is a genetic condition characterized by numerous somatic manifestations. The psychosocial burden in adults has rarely been studied. We examined the prevalence of self-reported impairment of quality of life (QoL), symptoms of anxiety and depression and need for support, associated with disease severity and visibility. We conducted a nationwide cross-sectional study of all 467 adults with NF1 diagnosed between 1977 and 2016 at one of the two national centers for rare diseases in Denmark. A total of 244 (56% response rate) completed a questionnaire that included standard measures of QoL, symptoms of depression and anxiety, indicators of disease-related severity, visibility, and need for professional support. Associations between disease severity and visibility and psychosocial burden were analyzed in descriptive and multivariate models. We observed impaired QoL (mean = 81.3; 95% CI, 76.2; 86.4); 19% reported symptoms of depression (mean = 5.7; SD = 5.4), and 15% reported anxiety (mean = 5.1; SD = 5.2) at a clinical level. Adults with NF1 also reported requiring professional support for physical, psychological, and work-related problems. Disease severity and (partly) visibility were significantly (p < .0001) associated with psychosocial well-being and a requirement for support. This study provides new understanding of the factors associated with impaired QoL, indicating that follow-up care should be optimized into adult life.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  adults; nationwide; need for support; neurofibromatosis type 1; population-based; psychosocial burden

Mesh:

Year:  2020        PMID: 32484306     DOI: 10.1002/ajmg.a.61627

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  5 in total

1.  The mediating effects of quality of life, depression, and generalized anxiety on perceived barriers to employment success for people diagnosed with Neurofibromatosis Type 1.

Authors:  Frank D Buono; Matthew E Sprong; Erina Paul; Staci Martin; Kaitlyn Larkin; Amir Garakani
Journal:  Orphanet J Rare Dis       Date:  2021-05-21       Impact factor: 4.123

2.  The psychological impact and experience of breast cancer screening in young women with an increased risk of breast cancer due to neurofibromatosis type 1.

Authors:  Ashley Crook; Rebekah Kwa; Sarah Ephraums; Mathilda Wilding; Lavvina Thiyagarajan; Jane Fleming; Katrina Moore; Yemima Berman
Journal:  Fam Cancer       Date:  2021-05-08       Impact factor: 2.446

3.  Assessing Psychiatric Comorbidity and Pharmacologic Treatment Patterns Among Patients With Neurofibromatosis Type 1.

Authors:  Alexander C Houpt; Shaina E Schwartz; Robert A Coover
Journal:  Cureus       Date:  2021-12-07

4.  Transition to adult care of young patients with neurofibromatosis type 1 and cognitive deficits: a single-centre study.

Authors:  S Lausdahl; M M Handrup; S L Rubak; M D Jensen; C Ejerskov
Journal:  Orphanet J Rare Dis       Date:  2022-05-21       Impact factor: 4.123

5.  Cohort profile: life with neurofibromatosis 1 - the Danish NF1 cohort.

Authors:  Karoline Doser; Hanne Hove; John R Østergaard; Pernille E Bidstrup; Susanne O Dalton; Mette Møller Handrup; Cecilie Ejerskov; Anja Krøyer; Mia Aagaard Doherty; Jens Richardt Møllegaard Jepsen; John J Mulvihill; Jeanette F Winther; Line Kenborg
Journal:  BMJ Open       Date:  2022-09-20       Impact factor: 3.006

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.